Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fructooligosaccharide + lactobacillus crispatus 197 + lactobacillus gasseri CCFM1201
- Development stage
- Preclinical
- Lead developer
- Tate & Lyle
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Fructooligosaccharide + Lactobacillus crispatus 197 + Lactobacillus gasseri CCFM1201 is a synbiotic combination product designed to support women's vaginal health. It combines a prebiotic (fructooligosaccharide) with two strains of probiotic bacteria. Fructooligosaccharides (FOS) are non-digestible fibers that act as a food source for beneficial bacteria, promoting their growth and activity. *Lactobacillus crispatus* is a key species for a healthy vaginal microbiome, known to produce lactic acid which helps maintain an acidic environment (pH < 4.5) that is inhospitable to pathogens. [10, 14] The specific strain *Lactobacillus gasseri* CCFM1201 has been studied for its ability to inhibit *Gardnerella vaginalis*, the primary pathogen associated with bacterial vaginosis (BV). [13] In preclinical models, *L. gasseri* CCFM1201 has been shown to inhibit biofilm formation, modulate local immune responses by reducing pro-inflammatory cytokines, and help restore the structure of vaginal tissue. [1, 12, 13] This combination aims to restore and maintain a healthy vaginal flora, thereby preventing and managing vaginal dysbiosis such as bacterial vaginosis.
- Other names
- 低聚果糖 + 卷曲乳杆菌197 + 格式乳杆菌CCFM1201
Beyond the preview
Go deeper on fructooligosaccharide + lactobacillus crispatus 197 + lactobacillus gasseri CCFM1201.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fructooligosaccharide + lactobacillus crispatus 197 + lactobacillus gasseri CCFM1201.